Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm durvalumab + AZD6738 in relapsed small cell lung cancer
KCT0005058Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, ceralasertib in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Jun 2020; status: completed.
02
Drugs
durvalumabceralasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0005058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005058.